Market Research Reports and Industry Reports

High-Growth Diagnostic Testing Markets

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

1. Overview 12
 1.1 Statement of Report 12
 1.2 Scope of This Report 13
 1.3 Methodology 14
 1.4 Executive Summary 15
 
 2. Introduction to the High-Growth Testing Market 25
 2.1 Introduction to the Global Diagnostic Market 25
 2.2 General Areas with Potential for High-Growth Testing 26
 2.3 Market Drivers in the High-Growth Diagnostics Testing Sector 28
 2.4 Market Segments for High-Growth Testing 28
 2.5 Key Players in the High-Growth Diagnostics Testing Segment 28
 2.6 High-Growth Testing Sector Analysis 30
 
 3. Hepatitis Serologic Markers and Nucleic Acid Testing 31
 3.1 Hepatitis B Virus (HBV) 31
 3.2 Major Suppliers of Hepatitis B Virus (HBV) Testing Products 39
 3.3 Market Revenue Analysis 42
 3.4 Hepatitis C Virus (HCV) Testing 43
 3.5 Market Revenue Analysis 52
 3.6 Market Share Analysis 52
 
 4. Human Papillomavirus (HPV) Testing 54
 4.1 Overview 54
 4.2 The Association of HPV and Cervical Cancer 57
 4.3 The PAP Test 59
 4.4 Current Laboratory Methods for HPV Detection 59
 4.4.1 Direct-Probe Methods 59
 4.4.2 Signal Amplification 59
 4.4.3 Target Amplification 59
 4.5 Assays for HPV 60
 4.6 Market Revenue Analysis 68
 4.7 Competitor Activity 69
 4.8 Market and Technology Trends 71
 4.8.1 Market Trends 71
 4.8.2 Technology Trends 72
 
 5. HIV 75
 5.1 Introduction to HIV/AIDS 75
 5.2 Statistical Data Global HIV/AIDS Epidemic 75
 5.3 HIV Prevention and Treatment 78
 5.3.1 HIV Prevention 78
 5.3.2 HIV Treatment 78
 5.4 U.S. Testing Market 79
 5.5 Market Dynamics 81
 5.5.1 Market Drivers 81
 5.5.2 Market Restraints 82
 5.5.3 Market Trends 83
 5.5.4 Technology Trends 85
 5.6 Review of Selected HIV Testing Devices 86
 5.7 Market Revenue Analysis 92
 5.8 Competitor Activity 93
 5.9 HIV Market Challenges and Strategic Recommendations 95
 5.10 Insurance Coverage and Reimbursement 96
 5.11 Policies Affecting HIV Testing 97
 5.12 Recent Industry Activity 97
 
 6. Infectious Disease Testing 100
 6.1 Introduction to Infectious Disease Testing 100
 6.2 Types of Diagnosis for Infectious Diseases 101
 6.2.1 Microbial Culture 101
 6.2.2 Microscopy 101
 6.2.3 Biochemical Tests 101
 6.2.4 Molecular Diagnostics 101
 6.3 Diagnostic Platforms for Infectious Diseases 102
 6.3.1 Centralized Laboratory Testing for Infectious Diseases 102
 6.3.2 POC Testing for Infectious Diseases 102
 6.4 Emerging Technologies 103
 6.5 Qualitative Analysis 103
 6.5.1 Market Drivers 103
 6.5.2 Market Restraints 104
 6.6 Streptococcus Testing 104
 6.7 Chlamydia Testing 109
 6.8 Mononucleosis 114
 6.9 Gonorrhea 116
 6.10 Influenza 120
 6.11 Malaria 122
 6.12 Tuberculosis 131
 6.13 Methicillin-Resistant Staphylococcus Aureus (MRSA) 143
 6.14 Market Revenue Analysis 146
 
 7. Cardiac Markers 147
 7.1 Market Overview 147
 7.2 Cardiac Marker Tests 147
 7.2.1 Creatine Kinase (CK) 147
 7.2.2 Myoglobin 148
 7.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 148
 7.2.4 C-Reactive Protein (CRP) 148
 7.2.5 Homocysteine 149
 7.3 Emerging Markers 149
 7.3.1 B-type Natriuretic Peptide (BNP) 149
 7.3.2 Myeloperoxidase (MPO) 149
 7.3.3 Ischemia Modified Albumin (IMA) 150
 7.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 150
 7.3.5 Fatty Acid-Binding Proteins (FABPs) 150
 7.4 Qualitative Analysis 151
 7.4.1 Market Drivers 151
 7.4.2 Market Restraints 152
 7.5 Specific Cardiac Conditions 152
 7.5.1 Acute Myocardial Infarction 152
 7.5.2 Heart Failure (BNP) 154
 7.5.2.1 Market Overview 154
 7.5.2.2 Commercial Assays for BNP and NT-proBNP 155
 7.5.2.3 Clinical Applications of BNP 156
 7.5.3 CRP 159
 7.6 Pulmonary Embolism (D-dimer Test) 160
 7.7 Key Players 161
 7.8 Market Revenue Analysis 168
 
 8. Cytogenetic Testing 170
 8.1 Cancer Testing 171
 8.2 Prenatal Testing and Cytogenetics 173
 8.2.1 Cystic Fibrosis Testing 174
 8.2.1.1 CF Testing Methodology 175
 8.2.1.2 CF Screening Technology Summary 178
 8.3 Key Players in Segment 179
 
 9. Fertility Testing 180
 
 10. Cancer Biomarker Testing 184
 10.1 Segment Overview 184
 10.2 The Cancer Testing Market 185
 10.3 Competition 190
 10.4 Individual Markets 190
 10.4.1 Cancer Pathology: Testing 190
 10.4.1.1 Rare Cell/Micro Metastasis Detection 191
 10.4.1.2 Cancer Pathology: High-Throughput Screening 192
 10.4.1.3 Competition 193
 10.4.1.4 Drivers 194
 10.4.2 Breast Cancer 194
 10.4.2.1 CA 15-3 196
 10.4.2.2 CA 27-29 196
 10.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes 197
 10.4.2.4 Estrogen and Progesterone Receptor (ER and PR) 199
 10.4.2.5 Human Epidermal Growth Factor Receptor 2 (HER-2) 199
 10.4.2.6 Herceptin 200
 10.4.2.7 p53 200
 10.4.2.8 Nuclear Matrix Protein 66 (NMP66) 200
 10.4.2.9 Mammastatin 201
 10.4.2.10 Drivers for Breast Cancer Test Development 201
 10.4.3 Ovarian Cancer 202
 10.4.3.1 Cancer Antigen 125 (CA 125) 203
 10.4.3.2 BRCA1 and BRCA2 203
 10.4.3.3 Steroid Hormone Receptors 204
 10.4.3.4 Epidermal Growth Factor Receptor (EGFR) 204
 10.4.3.5 Lysophospholipids 206
 10.4.4 Cervical Cancer 206
 10.4.4.1 Cervical Cancer Screening Tests 208
 10.4.5 Colon Cancer DNA Testing 209
 10.5 Pharmacogenomic Cancer Testing 211
 10.6 Market Revenue Analysis 214
 
 11. Substance Abuse Testing 216
 11.1 Background to POC Substance Abuse Testing 216
 11.2 Substance Abuse Test Types 223
 11.2.1 Urine Substance/Drug Screening 223
 11.2.2 Hair Tests for Substance Abuse and Screening 223
 11.2.3 Blood Tests for Substance Abuse and Screening 224
 11.2.4 Saliva Tests for Substance Abuse and Screening 224
 11.2.5 Sweat Tests for Substance Abuse and Screening 224
 11.3 Alcohol Abuse and Screening 224
 11.4 Saliva Testing 225
 11.5 Qualitative Analysis 225
 11.5.1 Market Drivers 225
 11.5.2 Market Restraints 226
 11.6 Review of Selected POC Substance Abuse Analyzers 226
 11.7 Review of Company Products 228
 11.7.1 Alere 228
 11.7.2 Abbott Diagnostics 228
 11.7.3 Roche Diagnostics 229
 11.7.4 BioScan Screening Systems, Inc. 230
 11.7.5 American Bio Medica Corp. 230
 11.7.6 Phamatech, Inc. 233
 11.7.7 First Check Medical 234
 11.7.8 OraSure 234
 11.7.9 Avitar, Inc. 235
 11.7.10 Concateno (Alere, Inc.) 235
 11.7.11 Pathtech 235
 11.7.12 Alfa Scientific Designs, Inc. 236
 11.7.13 TCPI, Inc. 237
 11.7.14 Roche 237
 11.7.15 Biophor Diagnostics 237
 11.7.16 Randox Laboratories 237
 11.7.17 Branan Medical 238
 11.7.18 Concateno 238
 11.8 Market Revenue Analysis 239
 
 12. Vitamin D Diagnostic Testing 240
 12.1 Market Revenue Analysis 244
 
 13. Renal Dialysis Testing 245
 
 14. Companion Diagnostics 246
 14.1 Market Revenue Analysis 247
 
 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 249
 15.1 Summary Analysis of the Global IVD Market 249
 15.2 Summary Analysis of the Global IVD High-Growth Market by Geographic Region 252
 15.3 U.S.: Summary Analysis of the IVD High-Growth Market 253
 15.3.1 U.S.: Summary of IVD High-Growth Market 254
 15.3.2 Cardiac Markers 256
 15.4 Europe: Summary Analysis of the IVD High-Growth Market 259
 15.4.1 Summary of IVD High-Growth Market Europe 263
 15.5 Brazil: Summary Analysis of the IVD High-Growth Market 266
 15.5.1 Summary of IVD High-Growth Market Brazil 267
 15.6 Russia: Summary Analysis of the IVD High-Growth Market 269
 15.6.1 Summary of IVD High-Growth Market Russia 270
 15.7 India: Summary Analysis of the IVD High-Growth Market 272
 15.7.1 Summary of IVD High-Growth Market India 279
 15.8 China: Summary Analysis of the IVD High-Growth Market 281
 15.8.1 Summary of IVD High-Growth Market China 297
 15.9 South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market 299
 15.9.1 Japan 300
 15.9.2 South Korea 303
 15.9.3 Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia 305
 15.9.4 Summary of IVD High-Growth Market Other Asia 307
 
 16. Clinical Laboratory Genomics 309
 16.1 Introduction 309
 16.2 Clinical Laboratory Genomics Testing 310
 16.3 Developments in Clinical Laboratory Genomics 311
 16.3.1 Nucleic Acid Amplification Techniques 311
 16.3.2 Chromosome Imaging 312
 16.3.3 Genomics Technologies 312
 16.3.4 Proteomics Technology 313
 16.3.5 Current Pharmacogenomic Tests 313
 16.3.6 Future Pharmacogenomic Testing 314
 
 17. Cellular Imaging Cytopathology and Histopathology 316
 17.1 Segment Overview 316
 17.2 The Market 316
 17.3 Market Drivers 318
 17.4 Market Restraints 318
 17.5 Cytology and Histology Technology Platforms 318
 17.5.1 Cytology Screening Procedures and Pap Smear Technology 319
 17.5.2 Histology 324
 17.5.3 Market Drivers 326
 17.5.4 ISH Staining 326
 17.5.5 Special-Stains Staining 326
 17.6 Third-Party Reimbursement 326
 17.7 Competition 327
 
 18. High-Growth Testing Diagnostic Trends 332
 18.1 Genetic Testing 332
 18.2 Quality Measures 332
 18.3 Moderators of Growth 332
 18.3.1 Diagnostics and the Aging Population 332
 18.3.2 Individualized Medicine 332
 18.3.3 Genetic Testing 332
 18.4 Workforce Issues 334
 18.5 Reimbursement 334
 18.5.1 Cardiovascular 335
 18.5.2 Screening for Diabetes 336
 18.5.3 CPT Test Codes and Payment Amounts 336
 18.6 Rapid Near-Patient Testing in Hospitals 339
 18.7 Satellite Facilities 339
 18.8 Regionalization of Laboratory Care 340
 18.9 Requirements for High-Growth Testing 341
 18.10 Clinical Laboratory Improvement Act (CLIA) 342
 
 19. Important Technology Trends 345
 
 20. Molecular Diagnostics a Major Diagnostic Technological Advance 348
 20.1 Polymerase Chain Reaction (PCR)-based Molecular Diagnostics 349
 20.2 Micrarray Technologies and Molecular Diagnostics 350
 20.3 Isothermal Amplification Technologies and Molecular Diagnostics 351
 20.4 Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip) 352
 
 21. Technology Platform Innovations in POCT 354
 21.1 Latest POCT Technological Platforms 354
 21.1.1 Device Miniaturization and Microfluidic Technologies 354
 21.1.2 Minimally-Invasive and Non-Invasive POCT Technologies 354
 21.1.3 Advances in Wireless Technologies 355
 21.1.4 Automation of POCT 355
 21.1.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing
 Technologies) 355
 21.1.6 Advances in Informatics Technologies 357
 21.1.7 Pharmacogenetic Testing 358
 21.1.8 Multi Assay Technologies in POCT 358
 21.2 Developments in Key Technologies 358
 21.2.1 Medical and Biological Sensors and Sensor Systems 358
 21.2.2 Recent Biosensor Product Introductions and Latest Innovative Developments 360
 21.2.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers 360
 21.2.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments 360
 21.2.2.3 ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor 360
 21.2.2.4 AgaMatrix Europe Limited Introduces the New Jazz Blood Glucose Meter in the U.K. 361
 21.2.2.5 STMicroelectronics to Manufacture Worlds Smallest Biosensors 361
 21.2.2.6 Universal Biosensors Advances Point of Care Molecular Diagnostic Opportunity 361
 21.2.2.7 Clinitek Advantus—A Semi Automated Urine Analyzer for Point of Care Testing 361
 21.2.2.8 The NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-Based Seven Test Chemistry Profile 361
 21.3 Sensor Systems for Diagnostic Applications 363
 21.4 Nanogen (The ELITech Group) Third Generation Point of Care Analyzer 366
 21.5 Philips Development of Magnotech Technology 366
 21.6 Quidel Corporation MChip, AVR Chip and F Chip 366
 21.7 Sanofi-Aventis 367
 
 22. Data Management and Connectivity 368
 22.1 Wireless LANs 368
 22.2 Connectivity Platforms 371
 22.2.1 DataLink Data Management System 371
 22.2.2 RALS-Plus 372
 22.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite 374
 22.2.2.2 Siemens Diagnostics Rapidpoint Coag 374
 22.2.2.3 Radiometer 374
 22.2.2.4 HemoCue’s DM Hemoglobin 374
 22.2.2.5 Roche Diagnostics 374
 22.2.3 BD.id 375
 22.2.4 Medical Implant Communications Service (MICS) 375
 22.2.5 Conworx Technology 375
 22.2.6 Lab Data Systems 376
 22.2.7 Medasys 376
 22.2.8 NoemaLife 376
 22.3 Advantages of POCT Connectivity 377
 22.3.1 Cost Benefit of POCT and IT Connectivity 377
 22.3.2 Hospital Network Issues 377
 22.4 POCT Analyzer Connectivity Software Solutions 378
 22.5 POCT2-P 380
 
 23. Biochips for Clinical Applications 381
 23.1 Roche AmpliChip 389
 23.2 Amersham CodeLink 391
 23.3 Breast Cancer DNA Chips 391
 23.4 Osmetech eSensor 391
 23.5 Affymetrix GeneChip System 3000Dx v.2 392
 23.6 Caliper and Cepheid 392
 23.7 Agilent Technologies 2100 Lab-on-a-Chip 392
 
 24. Company Profiles 394
 24.1 Abaxis, Inc. 394
 24.2 Abbott Laboratories 396
 24.3 Accurex Biomedical Pvt. Ltd. 401
 24.4 Adeza Biomedical Corporation (Hologic) 401
 24.5 Agilent Technologies, Inc. 401
 24.6 Alere, Inc. 403
 24.7 Ambri Ltd. 405
 24.8 American Bio Medica Corporation 406
 24.9 Ani Biotech Oy Ltd. 409
 24.10 Applied Spectral Imaging 410
 24.11 Avitar, Inc. 411
 24.12 Axis-Shield Plc 412
 24.13 Bayer Corporation 413
 24.14 Beckman Coulter (now part of Danaher) 414
 24.15 Becton, Dickinson and Company 418
 24.16 Biomerica, Inc. 419
 24.17 Bio-Rad Laboratories, Inc. 420
 24.18 Calypte Biomedical Corporation 422
 24.19 Chembio Diagnostics, Inc. 423
 24.20 Cozart Bioscience Ltd. 423
 24.21 Denka Seiken Co., Ltd. 424
 24.22 diaDexus, LLC 424
 24.23 Enterix, Inc. (Subsidiary of Quest Diagnostics) 425
 24.24 EY Laboratories, Inc. 426
 24.25 Genetix (Molecular Devices) 426
 24.26 Genzyme Diagnostics 427
 24.27 Hologic Gen Probe 428
 24.28 Instrumentation Laboratory (IL)/Werfen Group 433
 24.29 Jiangnan Biotech 433
 24.30 Johnson & Johnson 434
 24.31 Kyowa Medex Co., Ltd. 435
 24.32 LifeAssays AB 435
 24.33 LifeScan 435
 24.34 Matritech 436
 24.35 A Menarini Diagnostics 437
 24.36 Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc.) 437
 24.37 Meridian Bioscience 438
 24.38 Medix Biochemica 438
 24.39 Myriad Genetics, Inc. 439
 24.40 NOVA Biomedical 441
 24.41 OraSure 442
 24.42 Pheromone Sciences Corporation 444
 24.43 Polymedco, Inc. 444
 24.44 Polymer Technology Systems, Inc. 446
 24.45 QIAGEN N.V. 446
 24.46 Quest Diagnostics, Inc. 449
 24.47 Quidel Corporation 450
 24.48 Radiometer Medical 455
 24.49 Roche Diagnostics 458
 24.50 Shanghai SIIC Kehua Biotech Co., Ltd. (Kehua Biotech) 461
 24.51 Shionogi & Co., Ltd. 461
 24.52 Siemens Healthcare Diagnostics 462
 24.53 Spectral Diagnostics, Inc. 463
 24.54 Trinity Biotech Plc 464
 24.55 Väsamed, Inc. 466


List Of Tables

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments 15
 Table 1.2: Market Trends in the High-Growth Diagnostics Space 17
 Table 1.3: Worldwide Geographic Distribution of Total IVD Testing Market, 2012 20
 Table 1.4: Top 13 Country IVD Testing Markets, 2012 20
 Table 1.5: Company Market Share for IVD Testing Markets, 2012 21
 Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 22
 Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018 22
 Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 23
 Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 23
 Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections 35
 Table 3.2: Lower Detection Limits of HBV DNA Assays 36
 Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by
 Technology 40
 Table 3.4: Global Revenue Forecasts for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018 42
 Table 3.5: Global Revenue Forecasts for Hepatitis B Virus (HBV) Diagnostic Testing, 2008-2018 43
 Table 3.6: Efficiency of Available HCV Screening Tests 47
 Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C 48
 Table 3.8: Hepatitis C Statistics 49
 Table 3.9: Novartis Diagnostics Clinical Diagnostic Products Test for the Detection of HCV 51
 Table 3.10: Global Revenue Forecasts for Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018 52
 Table 3.11: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2012 52
 Table 4.1: HPV Risk Factors 55
 Table 4.2: HPV and Cervical Carcinoma 55
 Table 4.3: Key Statistics on Cervical Cancer in the World, 2011 56
 Table 4.4: Deaths in Thousands from Cervical Cancer by Region and by Age Group in 2011 57
 Table 4.5: Reflex HPV Testing with Cytology 62
 Table 4.6: Predictability of HPV Test by Abnormal Pap Smear Type 62
 Table 4.7: Qiagen’s Digene HC2 High-Risk HPV DNA Test 63
 Table 4.8: Commercially Available Molecular Diagnostic Products for HPV Assay 68
 Table 4.9: Long-Term Trends in HPV Testing 68
 Table 4.10: Global Revenue Forecasts for Human Papillomavirus (HPV) Diagnostic Testing, 2008-2018 69
 Table 5.1: Global HIV Statistics, 2011 76
 Table 5.2: Antiretroviral Therapy in Low- and Middle-Income Countries by Region, December 2011 79
 Table 5.3: Diagnosis of HIV Infection in 2011 for the U.S. and Six Dependent Areas 80
 Table 5.4: Estimated Number of AIDS Infection, 2011 81
 Table 5.5: Drivers of Demand for HIV Diagnostic Testing 82
 Table 5.6: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact 82
 Table 5.7: Drivers of Demand for HIV Diagnostic Testing 83
 Table 5.8: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact 83
 Table 5.9: Selected POC Infectious Disease Testing Devices, 2011 86
 Table 5.10: Commercially Available Molecular Diagnostic Products for HIV Assay 92
 Table 5.11: Global Revenue Forecasts for HIV and AIDS Diagnostic Testing, 2008-2018 92
 Table 5.12: Competitive Factors Related to HIV Tests 94
 Table 6.1: Rapid Strep Tests on the Market 105
 Table 6.2: U.S. Chlamydia Infection Rates, 1985-2011 110
 Table 6.3: Rapid Tests for Chlamydia 111
 Table 6.4: Rapid Tests for Gonorrhea 117
 Table 6.5: Commercially-available Rapid Tests for Malaria 129
 Table 6.6: Estimated TB Incidence, Prevalence and Mortality, 2011 136
 Table 6.7: FIND Partners 140
 Table 6.8: Global Market Potential for TB Diagnostic Testing, 2000-2012 143
 Table 6.9: MRSA Diagnostics Currently on the Market 145
 Table 6.10: Global Revenue Infectious Disease Revenue Analysis, 2008-2018 146
 Table 7.1: Medication Chart for Cardiovascular Disease 151
 Table 7.2: BNP Clinical Characteristics 155
 Table 7.3: Cardiovascular Risk Classification by CRP Level 160
 Table 7.4: Clinical Characteristics of D-dimer 160
 Table 7.5: Global Revenue Forecasts for Cardiac Marker Testing, 2008-2018 169
 Table 8.1: Genetic Testing: Consequences and Challenges 174
 Table 8.2: CF Carrier Risk by Ethnic Group 174
 Table 8.3: Reasons for CF Testing 175
 Table 8.4: CF Gene Detection Rates Vary by Ethnic Background 176
 Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018 177
 Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018 177
 Table 8.7: Commercial CF Screening Products 178
 Table 8.8: Emerging CF Screening Products 178
 Table 9.1: The Fertility Testing Market in the U.S., 2008-2018 180
 Table 10.1: Organ-Specific Medicines in Development for Cancer 186
 Table 10.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2013 187
 Table 10.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2013 187
 Table 10.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Men 187
 Table 10.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Women 188
 Table 10.6: Estimated Age-Standardized Incidence and Mortality Rates Per 100,000 by World Area, 2008 189
 Table 10.7: Worldwide CA 15-3 Sales, 2009-2019 196
 Table 10.8: TPA Marker Sensitivity 199
 Table 10.9: Worldwide CA 125 Sales, 2009-2019 202
 Table 10.10: INFINITI Applications 214
 Table 10.11: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018 215
 Table 11.1: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department 221
 Table 11.2: Stat Urine Testing Drug Recommendations 222
 Table 11.3: Selected POC Substance/Drug Abuse Testing Devices, 2011 226
 Table 11.4: Selected POC Substance/Drug Abuse Testing Devices, OraSure, 2011 234
 Table 11.5: Selected Target Substances and Drugs, 2011 235
 Table 11.6: Global Revenue Forecasts for Substance Abuse Testing, 2008-2018 239
 Table 12.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018 244
 Table 14.1: Companion Biomarker Market Size, 2008-2018 248
 Table 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012 249
 Table 15.2: Top 13 Country IVD Testing Markets, 2012 250
 Table 15.3: Company Market Share for IVD Testing Markets, 2012 251
 Table 15.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 252
 Table 15.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 252
 Table 15.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 253
 Table 15.7: Summary of IVD High-Growth Market U.S., 2011 254
 Table 15.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S.,
 2008-2018 254
 Table 15.9: U.S. Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 255
 Table 15.10: U.S. Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
 2008-2018 255
 Table 15.11: Specific Cardiac Markers 256
 Table 15.12: Cardiac Markers after Onset o


List Of Figures

Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012 20
 Figure 1.2: Top 13 Country IVD Testing Markets, 2012 21
 Figure 1.3: Company Market Share for IVD Testing Markets, 2012 21
 Figure 3.1: Geographic Distribution of Chronic HBV Infection 32
 Figure 3.2: Evolution of HBV Markers in Acute and Chronic Infection 39
 Figure 3.3: U.S. Market Share of HCV Molecular Diagnostic Market, 2012 53
 Figure 3.4: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2012 53
 Figure 4.1: PCR Analytical Sensitivity Detection Limits 64
 Figure 4.2: The Basic Steps of Hybrid Capture 2 Technology 65
 Figure 4.3: Diagram of Qiagen QIAsymphony SP/AS instrument 66
 Figure 5.1: Global View of HIV Infection, 2009 76
 Figure 5.2: Global Trend of HIV Infection, 1991-2011 77
 Figure 5.3: Number of People Living with HIV, Newly Infected with HIV and Number of AIDS Deaths in the World, 1990-2011 77
 Figure 5.4: Worldwide Rate of New HIV Cases, 1990-2011 78
 Figure 5.5: Number of People Receiving Antiretroviral Therapy in Low- and Middle-Income Countries, by Region, 2003-2012 (with Projection) 79
 Figure 6.1: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2011 117
 Figure 6.2: Global Incidence of Malaria 123
 Figure 6.3: Mode of Action of Common Malaria RDT Format 126
 Figure 6.4: Rate of Tuberculosis (TB) Cases by State/Area in the U.S., 2011 135
 Figure 6.5: FIND Pipeline for TB Diagnostics 139
 Figure 10.1: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions 207
 Figure 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012 250
 Figure 15.2: Top 13 Country IVD Testing Markets, 2012 251
 Figure 15.3: Company Market Share for IVD Testing Markets, 2012 251
 Figure 15.4: Indian Diagnostics Market Segments, 2011 276
 Figure 15.5: The Chinese Healthcare System 282
 Figure 17.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females, 2011 320
 Figure 17.2: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions 322


High-Growth Diagnostic Testing Markets

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the

USD 5500View Report

2016-2021 Emerging US Diagnostic Testing Market: Segment Forecasts and Supplier Shares by Test

This new report from VPGMarketResearch.com provides an overview of the US diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume

USD 5400View Report

2016-2021 Emerging UK Diagnostic Testing Market: Segment Forecasts and Supplier Shares by Test

This new report from VPGMarketResearch.com provides an overview of the UK diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume

USD 4850View Report

2016-2021 Emerging Spanish Diagnostic Testing Market: Segment Forecasts and Supplier Shares by Test

This new report from VPGMarketResearch.com provides an overview of the Spanish diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume

USD 4850View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 5500
  • 10 User Licence    $ 11000
  • Enterprise Wide Licence    $ 165000200
$ 5500

Reports Details

Published Date : Jan 2016
No. of Pages :355
Country :Global
Category :Healthcare
Publisher :TriMark Publications, LLC
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment